Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 5083463, 8 pages
https://doi.org/10.1155/2017/5083463
Case Report

EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in ASXL1, BCOR, CDKN2A, NF1, and TP53

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA

Correspondence should be addressed to Agata M. Bogusz; ude.nnepu.shpu@zsugob.ataga

Received 25 October 2016; Revised 18 February 2017; Accepted 19 March 2017; Published 10 April 2017

Academic Editor: Yusuke Shiozawa

Copyright © 2017 Agata M. Bogusz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, N. L. Harris et al., WHO Classsification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008.
  2. J. Morscio, D. Dierickx, and T. Tousseyn, “Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?” Clinical and Developmental Immunology, vol. 2013, Article ID 150835, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Swerdlow, E. Campo, S. A. Pileri et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, vol. 127, no. 20, pp. 2375–2390, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. D. A. Thorley-Lawson and A. Gross, “Persistence of the Epstein-Barr virus and the origins of associated lymphomas,” New England Journal of Medicine, vol. 350, no. 13, pp. 1328–1337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. B. P. Nelson, M. A. Nalesnik, D. W. Bahler, J. Locker, J. J. Fung, and S. H. Swerdlow, “Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?” American Journal of Surgical Pathology, vol. 24, no. 3, pp. 375–385, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. Taylor, R. Marcus, and J. A. Bradley, “Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation,” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 155–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Dotti, R. Fiocchi, T. Motta et al., “Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant,” Transplantation, vol. 69, no. 5, pp. 827–833, 2000. View at Google Scholar · View at Scopus
  8. V. Leblond, F. Davi, F. Charlotte et al., “Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?” Journal of Clinical Oncology, vol. 16, no. 6, pp. 2052–2059, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. E. L. Courville, S. Yohe, D. Chou et al., “EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations,” Modern Pathology, vol. 29, pp. 1200–1211, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Finalet Ferreiro, J. Morscio, D. Dierickx et al., “EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features,” American Journal of Transplantation, vol. 16, no. 2, pp. 414–425, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Hatem, A. M. Schrank-Hacker, C. D. Watt et al., “Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report,” Diagnostic Pathology, vol. 11, no. 1, article 137, 2016. View at Publisher · View at Google Scholar
  12. C. E. Sloan, M. R. Luskin, A. M. Boccuti et al., “A modified integrated genetic model for risk prediction in younger patients with acute myeloid leukemia,” PLoS ONE, vol. 11, no. 4, Article ID e0153016, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. Patel, M. Gönen, M. E. Figueroa et al., “Prognostic relevance of integrated genetic profiling in acute myeloid leukemia,” New England Journal of Medicine, vol. 366, no. 12, pp. 1079–1089, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Daber, S. Sukhadia, and J. J. D. Morrissette, “Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets,” Cancer Genetics, vol. 206, no. 12, pp. 441–448, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Al-Mansour, B. P. Nelson, and A. M. Evens, “Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies,” Current Hematologic Malignancy Reports, vol. 8, no. 3, pp. 173–183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. R. Ambrosio, B. J. Rocca, A. Ginori et al., “A look into the evolution of Epstein-Barr virus-induced lymphoproliferative disorders: a case study,” American Journal of Clinical Pathology, vol. 144, no. 5, pp. 817–822, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. R. Luskin, D. S. Heil, K. S. Tan et al., “The Impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder,” American Journal of Transplantation, vol. 15, no. 10, pp. 2665–2673, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. F. E. Craig, L. R. Johnson, S. A. K. Harvey et al., “Gene expression profiling of epstein-barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders,” Diagnostic Molecular Pathology, vol. 16, no. 3, pp. 158–168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. P. Hans, D. D. Weisenburger, T. C. Greiner et al., “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray,” Blood, vol. 103, no. 1, pp. 275–282, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. X. J. Wang, L. Jeffrey Medeiros, C. E. Bueso-Ramos et al., “P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma,” Modern Pathology, vol. 30, no. 2, pp. 194–203, 2016. View at Publisher · View at Google Scholar
  21. Y. Xie, M. Ajaz Bulbul, L. Ji et al., “P53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: A Single Institutional Clinicopathologic Study,” American Journal of Clinical Pathology, vol. 141, no. 4, pp. 593–604, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Alvarez Argote and C. A. Dasanu, “ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival,” Current Medical Research and Opinion, 2017. View at Publisher · View at Google Scholar
  23. V. Quesada, L. Conde, N. Villamor et al., “Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia,” Nature Genetics, vol. 44, no. 1, pp. 47–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Gelsi-Boyer, M. Brecqueville, R. Devillier, A. Murati, M.-J. Mozziconacci, and D. Birnbaum, “Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases,” Journal of Hematology and Oncology, vol. 5, article 12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Basso and R. Dalla-Favera, “Roles of BCL6 in normal and transformed germinal center B cells,” Immunological Reviews, vol. 247, no. 1, pp. 172–183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Dobashi, N. Tsuyama, R. Asaka et al., “Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type,” Genes Chromosomes and Cancer, vol. 55, no. 5, pp. 460–471, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Dubois, P.-J. Viailly, S. Mareschal et al., “Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: A LYSA Study,” Clinical Cancer Research, vol. 22, no. 12, pp. 2919–2928, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. M. B. Møller, Y. Ino, A.-M. Gerdes, K. Skjødt, D. N. Louis, and N. T. Pedersen, “Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma,” Leukemia, vol. 13, no. 3, pp. 453–459, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. A. K. Cani, M. Soliman, D. H. Hovelson et al., “Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies,” Modern Pathology, vol. 29, no. 7, pp. 685–697, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Morscio and T. Tousseyn, “Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders,” World Journal of Transplantation, vol. 6, no. 3, pp. 505–516, 2016. View at Publisher · View at Google Scholar